OBJECTIVES: Elevated plasma lipoprotein(a) [Lp(a)] is a significant risk factor for vascular disease. Standardization of Lp(a) mass measurement is complicated by the heterogeneity of apolipoprotein(a) [apo(a)]. We investigated whether Lp(a) cholesterol measurement, which is not influenced by apo(a) size, is a viable alternative to measuring Lp(a) mass. DESIGN AND METHODS: Plasma Lp(a) cholesterol was measured electrophoretically, with and without ultracentrifugation, and results were compared to each other and to immunoturbidimetrically measured Lp(a) mass in 470 subjects. RESULTS: Ultracentrifuged and whole plasma Lp(a) cholesterol levels demonstrated high correlation (R = 0.964). All samples with detectable (>/=2.0 mg/dl) Lp(a) cholesterol had Lp(a) mass >30 mg/dl (the clinically relevant cutpoint), while 59 samples with Lp(a) mass >30 mg/dl did not have detectable Lp(a) cholesterol. CONCLUSIONS: Lp(a) cholesterol can be measured in whole plasma without interference from VLDL lipoproteins. The relative clinical merits of measuring Lp(a) cholesterol vs. Lp(a) mass or both in combination deserves investigation.
OBJECTIVES: Elevated plasma lipoprotein(a) [Lp(a)] is a significant risk factor for vascular disease. Standardization of Lp(a) mass measurement is complicated by the heterogeneity of apolipoprotein(a) [apo(a)]. We investigated whether Lp(a)cholesterol measurement, which is not influenced by apo(a) size, is a viable alternative to measuring Lp(a) mass. DESIGN AND METHODS: Plasma Lp(a)cholesterol was measured electrophoretically, with and without ultracentrifugation, and results were compared to each other and to immunoturbidimetrically measured Lp(a) mass in 470 subjects. RESULTS: Ultracentrifuged and whole plasma Lp(a)cholesterol levels demonstrated high correlation (R = 0.964). All samples with detectable (>/=2.0 mg/dl) Lp(a)cholesterol had Lp(a) mass >30 mg/dl (the clinically relevant cutpoint), while 59 samples with Lp(a) mass >30 mg/dl did not have detectable Lp(a)cholesterol. CONCLUSIONS:Lp(a)cholesterol can be measured in whole plasma without interference from VLDL lipoproteins. The relative clinical merits of measuring Lp(a)cholesterol vs. Lp(a) mass or both in combination deserves investigation.
Authors: Patrick M Moriarty; Stephen A Varvel; Philip L S M Gordts; Joseph P McConnell; Sotirios Tsimikas Journal: Arterioscler Thromb Vasc Biol Date: 2017-01-05 Impact factor: 8.311
Authors: Atif N Qasim; Seth S Martin; Nehal N Mehta; Megan L Wolfe; James Park; Stanley Schwartz; Mark Schutta; Nayyar Iqbal; Muredach P Reilly Journal: Int J Cardiol Date: 2010-03-19 Impact factor: 4.164
Authors: Marija Tadin-Strapps; Michael Robinson; Lauretta Le Voci; Lori Andrews; Satya Yendluri; Stephanie Williams; Steve Bartz; Douglas G Johns Journal: J Cardiovasc Transl Res Date: 2015-01-21 Impact factor: 4.132
Authors: Weili Zheng; Michael Chilazi; Jihwan Park; Vasanth Sathiyakumar; Leslie J Donato; Jeffrey W Meeusen; Mariana Lazo; Eliseo Guallar; Krishnaji R Kulkarni; Allan S Jaffe; Raul D Santos; Peter P Toth; Steven R Jones; Seth S Martin Journal: J Am Heart Assoc Date: 2022-01-13 Impact factor: 6.106
Authors: Adam N Berman; David W Biery; Avinainder Singh; Wanda Y Wu; Sanjay Divakaran; Ersilia M DeFilippis; Jon Hainer; Michael J Blaha; Christopher Cannon; Donna M Polk; Jorge Plutzky; Pradeep Natarajan; Khurram Nasir; Marcelo F Di Carli; Deepak L Bhatt; Ron Blankstein Journal: Eur J Prev Cardiol Date: 2021-07-23 Impact factor: 8.526